| [공지] |
재조합 단백질 생산 flow 와 Master cell bank 구축 |
관리자 |
작성일20.04.16 |
조회416 |
| [공지] |
WHO guidelines on nonclinical evaluation of vaccines II |
관리자 |
작성일20.03.11 |
조회434 |
| [공지] |
Next generation of Whole cell Pneumococua vaccine |
관리자 |
작성일20.03.11 |
조회277 |
| [공지] |
Development_of_the_Sanofi_Pasteur_tetravalent_deng (1) |
관리자 |
작성일20.03.11 |
조회278 |
| 8 |
유전자 재조합 바이럿 개발과 안전 관리(강의용)
|
관리자 |
작성일22.08.16 |
조회219 |
| 7 |
바이러스 벡터 제조 시장 (Marketsandmarkets, Viral Vector, 2018)
|
관리자 |
작성일22.08.16 |
조회185 |
| 6 |
Characterizing Accidents, Exposures, and Laboratory-acquired Infections Reported to the National Institutes of Health’s Office of Biotechnology Activities (NIH/OBA) Div…
|
관리자 |
작성일22.08.16 |
조회154 |
| 5 |
Safety Pharmacology Evaluation of Biopharmaceuticals
|
관리자 |
작성일20.03.06 |
조회474 |
| 4 |
Preclinical Assessment of Investigational Cellular and Gene Therapy Products
|
관리자 |
작성일20.03.06 |
조회441 |
| 3 |
ICH Considerations Oncolytic Viruses
|
관리자 |
작성일20.02.20 |
조회553 |
| 2 |
Design and Analysis of Shedding Studies for Virus or Bacteria-Based Gene Therapy and Oncolytic Products
|
관리자 |
작성일20.02.20 |
조회537 |
| 1 |
Comparison of Regulations for the Development of Oncolytic Virus Therapy in the United States, the European Union, and Japan
|
관리자 |
작성일20.02.20 |
조회435 |
